Menu
← Oncology Approval Tracker
FDA DECISION ·
Cyclophosphamide injection (Nevakar)
cyclophosphamide · Nevakar Injectables
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
A 200 mg/mL IV solution for labeled adult and pediatric malignancies, including selected lymphomas and leukemias, multiple myeloma, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma and breast carcinoma.
LAMPGEN ANALYSIS
Why it matters
The distinct concentration adds a preparation option for several longstanding oncology indications.
What research teams should watch
Use the product-specific concentration, excipients and dilution procedure when building pharmacy instructions.
PRIMARY RECORDS